These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27660709)

  • 1. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.
    Uemura M; Fa'ak F; Haymaker C; McQuail N; Sirmans E; Hudgens CW; Barbara L; Bernatchez C; Curry JL; Hwu P; Tetzlaff MT; Diab A
    J Immunother Cancer; 2016; 4():55. PubMed ID: 27660709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.
    Koelzer VH; Buser T; Willi N; Rothschild SI; Wicki A; Schiller P; Cathomas G; Zippelius A; Mertz KD
    J Immunother Cancer; 2016; 4():47. PubMed ID: 27532022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.
    Uemura M; Fa'ak F; Haymaker C; McQuail N; Sirmans E; Hudgens CW; Barbara L; Bernatchez C; Curry JL; Hwu P; Tetzlaff MT; Diab A
    J Immunother Cancer; 2017; 5():7. PubMed ID: 28116090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoids for the Treatment of Refractory Grover's Disease: A Case Series and Review of the Literature.
    Moodie D; Dunn C; Fernandez C; Nathoo R
    Cureus; 2024 Feb; 16(2):e53510. PubMed ID: 38440005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient acantholytic dermatosis (Grover's disease) in a renal transplant patient.
    Boutli F; Voyatzi M; Lefaki I; Chaidemenos G; Kanitakis J
    J Dermatol; 2006 Mar; 33(3):178-81. PubMed ID: 16620222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.
    Koelzer VH; Rothschild SI; Zihler D; Wicki A; Willi B; Willi N; Voegeli M; Cathomas G; Zippelius A; Mertz KD
    J Immunother Cancer; 2016; 4():13. PubMed ID: 26981243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Rare Case of Transient Acantholytic Dermatosis (AKA. Grover's Disease) with Concomitant Pediculosis Pubis: An Atypical Presentation and First Documented Case Report.
    Pendlebury GA; Oro P; Merideth D; Rudnick E
    Dermatopathology (Basel); 2021 Oct; 8(4):502-508. PubMed ID: 34698112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermoscopy of Grover's disease: Variability according to histological subtype.
    Errichetti E; De Francesco V; Pegolo E; Stinco G
    J Dermatol; 2016 Aug; 43(8):937-9. PubMed ID: 26892381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and Treatment of Grover's Disease: A Case Report and Review of Literature.
    Sousou JM; Fritsche JM; Fernandez BR; Tummala MR; Scott R
    Cureus; 2022 Apr; 14(4):e24082. PubMed ID: 35573509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
    Cousin S; Italiano A
    Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
    Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
    Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
    Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
    Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grover's Disease after Heart Transplantation: A Case Report.
    Ippoliti G; Paulli M; Lucioni M; D'Armini AM; Lauriola M; Mahrous Haleem Saaleb R
    Case Rep Transplant; 2012; 2012():126592. PubMed ID: 23320241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.